尼莫地平治疗血管性非痴呆认知障碍的疗效观察

目的：探讨尼莫地平治疗血管性非痴呆认知障碍的改善作用。方法：76例血管性非痴呆认知障碍患者随机分为A组39例和B组37例。两组均给予常规治疗（包括阿司匹林片100 mg·d^-1,阿托伐他汀钙20 mg·d^-1）,A组在此基础上加用尼莫地平片30 mg,po,tid。疗程均为12周。治疗前后均运用蒙特利尔认知评分量表（MOCA）评分和简易精神状态评分量表（MMSE）对临床疗效进行评价。结果：治疗后,A组MMSE评分、MOCA评分均较治疗前明显提高（P〈0.05）,且显著高于B组评分（P〈0.05）。B组治疗前后两项评分差异均无统计学意义（P〉0.05）。A组总有效率明显高于B组（P〈0.05）。两组患者治疗过程中均未出现药品不良反应。结论：尼莫地平对血管性非痴呆认知障碍有防治作用。

Curative Effect of Nimodipine on Vascular Cognitive Impairment no Dementia

Objective： To investigate the curative effect of nimodipine on vascular cognitive impairment no dementia.Methods： Totally 76 patients with vascular cognitive impairment no dementia were randomly divided into group A with 39 cases and group B with 37 cases. The two groups were given conventional treatment（ aspirin tablets,100 mg · d^-1,and atorvastatin calcium tablets,20 mg·d^-1,The patients in group A were treated with nimodipine additionally,30 mg,po,tid. The course of treatment of the two groups was two weeks. The Montreal Cognitive Assessment（ MOCA） and mini-mental state examination（ MMSE） were used to evaluate the efficacy of the two groups before and after the treatment. Results： After the treatment,MMSE and MOCA scores in group A were increased significantly compared with those before the treatment（ P〈0. 05）,and significantly higher than those in group B after the treatment（ P〈0. 05）. The scores before and after the treatment in group B showed no significant difference（ P〉0. 05）. The total efficacy in group A was notably higher than that in group B（ P〈0. 05）. No patient experienced adverse drug reactions in both groups. Conclusion： Nimodipine has preventive and therapeutic effects on vascular cognitive impairment no dementia.